Engitix Licenses Lonza’s Technology to Advance ADC Therapies

PartnershipPositive

AI Analysis

Summary

Engitix has licensed technology from Lonza to advance antibody-drug conjugate (ADC) therapies, with Lonza eligible to receive upfront, milestone, and royalty payments based on product development and commercial success.

Importance:5/10

Sentiment:

0.50

licensingpartnershipADCtechnology transfer

Related Companies

$LONN.SW

Read the original article

Published by GEN - Genetic Engineering & Biotech News on July 22, 2026 12:00 PM

Read Original